Barclays
NAUT icon

Barclays’s Nautilus Biotechnolgy NAUT Stock Holding History

Barclays’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$149K Sell
105,225
-620,096
-85% -$736K ﹤0.01% 4132
2026
Q2 		$1.36M Buy
725,321
+651,996
+889% +$1.72M ﹤0.01% 2611
2026
Q1 		$285K Buy
73,325
+25,071
+52% +$61.6K ﹤0.01% 3496
2025
Q4 		$94.1K Hold
48,254
– – ﹤0.01% 4599
2025
Q3 		$40.8K Sell
48,254
-9,835
-17% -$7.23K ﹤0.01% 4813
2025
Q2 		$42.1K Sell
58,089
-42,878
-42% -$32.2K ﹤0.01% 4728
2025
Q1 		$86.9K Sell
100,967
-24,237
-19% -$36K ﹤0.01% 4456
2024
Q4 		$210K Buy
125,204
+19,030
+18% +$45.5K ﹤0.01% 4284
2024
Q3 		$303K Buy
106,174
+47,059
+80% +$122K ﹤0.01% 4086
2024
Q2 		$138K Sell
59,115
-17,979
-23% -$46.9K ﹤0.01% 3754
2024
Q1 		$227K Sell
77,094
-33,844
-31% -$96K ﹤0.01% 4053
2023
Q4 		$332K Buy
110,938
+60,392
+119% +$173K ﹤0.01% 4142
2023
Q3 		$160K Sell
50,546
-1,040
-2% -$3.38K ﹤0.01% 3396
2023
Q2 		$200K Sell
51,586
-14,456
-22% -$41.6K ﹤0.01% 3240
2023
Q1 		$183K Buy
66,042
+11,727
+22% +$24.6K ﹤0.01% 3847
2022
Q4 		$97.8K Buy
54,315
+10,778
+25% +$20.8K ﹤0.01% 4235
2022
Q3 		$92K Sell
43,537
-371
-0.8% -$933 ﹤0.01% 3568
2022
Q2 		$118K Buy
43,908
+2,392
+6% +$8.9K ﹤0.01% 3696
2022
Q1 		$180K Buy
+41,516
New +$170K ﹤0.01% 3487

Other funds holding NAUT

Cercano Management
Cercano Management Bellevue, Washington $729M AUM 20.71% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Clearstead Advisors
Clearstead Advisors Cleveland, Ohio $10.8B AUM 17.88% 1-Year Est. Return
Sentinel Trust
Sentinel Trust Houston, Texas $1.19B AUM 19.38% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Hillman Company
Hillman Company Pittsburgh, Pennsylvania $261M AUM 2.04% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Barclays's NAUT Position: Q3 2026 in Review

Barclays reduced its Nautilus Biotechnolgy (NAUT) stake by 85% in Q3 2026, selling an estimated $736K and leaving 105,225 shares worth $149K. The position accounts for ﹤0.01% of the portfolio, ranked #4132.

Barclays first reported a position in NAUT in Q1 2022 and has held it in 19 quarters since. The position peaked at $1.36M in Q2 2026. 38 funds tracked by Wall St. Rank hold NAUT as of Q3 2026.

  • Barclays held 105,225 shares of Nautilus Biotechnolgy worth $149K as of Q3 2026.
  • Barclays sold 620,096 Nautilus Biotechnolgy shares in Q3 2026, an estimated $736K.
  • Nautilus Biotechnolgy made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4132 holding.
  • Barclays first reported a position in Nautilus Biotechnolgy in Q1 2022 and has held it in 19 quarters since.
  • Barclays's Nautilus Biotechnolgy position peaked at $1.36M in Q2 2026.
  • 38 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.